Sanofi
SNYNF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $44,286,000 | $46,444,000 | $40,304,000 | $39,175,000 |
| % Growth | -4.6% | 15.2% | 2.9% | – |
| Cost of Goods Sold | $13,205,000 | $14,236,000 | $13,695,000 | $12,255,000 |
| Gross Profit | $31,081,000 | $32,208,000 | $31,694,000 | $26,920,000 |
| % Margin | 70.2% | 69.3% | 78.6% | 68.7% |
| R&D Expenses | $7,394,000 | $6,728,000 | $6,501,000 | $5,692,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $9,183,000 | $10,765,000 | $8,785,000 | $9,555,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $7,252,000 | $6,840,000 | $0 | $3,547,000 |
| Operating Expenses | $23,829,000 | $24,333,000 | $15,286,000 | $18,794,000 |
| Operating Income | $14,450,000 | $12,980,000 | $13,149,000 | $8,126,000 |
| % Margin | 32.6% | 27.9% | 32.6% | 20.7% |
| Other Income/Exp. Net | $0 | -$6,865,000 | -$3,157,000 | -$289,000 |
| Pre-Tax Income | $6,758,000 | $6,115,000 | $9,992,000 | $7,837,000 |
| Tax Expense | $1,204,000 | $1,017,000 | $1,909,000 | $1,558,000 |
| Net Income | $5,560,000 | $5,400,000 | $8,371,000 | $6,223,000 |
| % Margin | 12.6% | 11.6% | 20.8% | 15.9% |
| EPS | 4.45 | 4.3 | 6.69 | 4.97 |
| % Growth | 3.5% | -35.7% | 34.6% | – |
| EPS Diluted | 4.43 | 4.3 | 6.66 | 4.95 |
| Weighted Avg Shares Out | 1,249,400 | 1,255,814 | 1,251,900 | 1,252,500 |
| Weighted Avg Shares Out Dil | 1,256,100 | 1,256,400 | 1,256,900 | 1,257,900 |
| Supplemental Information | – | – | – | – |
| Interest Income | $413,000 | $19,000 | $239,000 | $3,000 |
| Interest Expense | $749,000 | $710,000 | $465,000 | $368,000 |
| Depreciation & Amortization | $3,586,000 | $2,955,000 | $3,108,000 | $2,686,000 |
| EBITDA | $11,033,000 | $11,076,000 | $13,510,000 | $11,251,000 |
| % Margin | 24.9% | 23.8% | 33.5% | 28.7% |